Amycretin (Zenagamtide)
GLP-1/amylin dual agonist, oral and injectable forms — Phase 3 underway, not yet FDA-approved.
Last Verified: August 14, 2026
Tier 2 — Investigational / Not Currently Approved Late-Stage Investigational
Amycretin (research/generic name zenagamtide) is not FDA-approved for any use. Its Phase 2 data is unusually strong and its Phase 3 program is actively enrolling, which is why it carries the late-stage flag rather than reading as a typical sparse-evidence Tier 2 entry. This page describes the mechanism and trial data — not dosing or usage guidance, and not a recommendation to use it. Talk to a doctor before considering it.
What It Is
Amycretin is a Novo Nordisk peptide that, like CagriSema, combines GLP-1 receptor activity with amylin receptor activity — but as a single unimolecular peptide rather than a co-formulated combination of two separate drugs. It's being developed in two forms: a once-daily oral tablet and a once-weekly subcutaneous injection, with separate development programs for type 2 diabetes and for obesity/overweight.
What the Trials Actually Show
In Phase 2 data, subcutaneous amycretin at 2.4 mg produced roughly 22% average body weight loss versus about 10.6% for semaglutide 2.4 mg at 26 weeks in adults with obesity or overweight — a notably larger effect size than semaglutide alone in that comparison. The oral form showed around 13.1% weight loss at 12 weeks in early-phase data. In a type 2 diabetes trial, once-weekly subcutaneous amycretin produced about 14.6% weight loss and put 89.1% of participants under an A1C of 7% at 36 weeks. As of early 2026, the Phase 3 obesity program was enrolling, with a Phase 3 diabetes program planned to start in the second half of 2026 — this is still investigational data, not a completed registrational program.
Patient Care Online — Novo's GLP-1/Amylin Dual Agonist Amycretin to Enter Late-Stage Trials for Obesity →
Current Regulatory Status — Watch This Space
Amycretin/zenagamtide is not FDA-approved and not available by prescription. Its Phase 3 program is earlier-stage than CagriSema's (which has already been filed) or retatrutide's and survodutide's (which have completed registrational trials) — it's the least far along of the late-stage entries on this page, even though its early data is strong. This status is likely to change as Phase 3 data reads out over the next couple of years — check back for updates.